<code id='4A7CEFDDDD'></code><style id='4A7CEFDDDD'></style>
    • <acronym id='4A7CEFDDDD'></acronym>
      <center id='4A7CEFDDDD'><center id='4A7CEFDDDD'><tfoot id='4A7CEFDDDD'></tfoot></center><abbr id='4A7CEFDDDD'><dir id='4A7CEFDDDD'><tfoot id='4A7CEFDDDD'></tfoot><noframes id='4A7CEFDDDD'>

    • <optgroup id='4A7CEFDDDD'><strike id='4A7CEFDDDD'><sup id='4A7CEFDDDD'></sup></strike><code id='4A7CEFDDDD'></code></optgroup>
        1. <b id='4A7CEFDDDD'><label id='4A7CEFDDDD'><select id='4A7CEFDDDD'><dt id='4A7CEFDDDD'><span id='4A7CEFDDDD'></span></dt></select></label></b><u id='4A7CEFDDDD'></u>
          <i id='4A7CEFDDDD'><strike id='4A7CEFDDDD'><tt id='4A7CEFDDDD'><pre id='4A7CEFDDDD'></pre></tt></strike></i>

          
          WSS
          Mark Lennihan/AP

          Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

          The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

          advertisement

          Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion